Literature DB >> 3768959

Chromosomal position or virus mutation permits retrovirus expression in embryonal carcinoma cells.

E Barklis, R C Mulligan, R Jaenisch.   

Abstract

Retrovirus expression is restricted in embryonal carcinoma (EC) cells. To study how a virus can overcome this block, we selected and analyzed rare proviruses that are expressed in F9 cells. Our results indicate that provirus expression occurs by two different mechanisms: one provirus acquired a single base pair mutation in the retrovirus tRNA primer binding site, permitting provirus expression; expression of three proviruses was mediated by 5'-flanking DNA sequences. Surprisingly, five proviruses in 17 selected cell lines integrated into the same two distinct chromosomal regions, suggesting that the number of chromosomal positions in the cellular genome that allows virus expression is very limited. Our results suggest that genomic sequences that are actively transcribed in EC cells can be isolated by selection for retrovirus expression.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768959     DOI: 10.1016/0092-8674(86)90596-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  117 in total

1.  Selection of functional tRNA primers and primer binding site sequences from a retroviral combinatorial library: identification of new functional tRNA primers in murine leukemia virus replication.

Authors:  A H Lund; M Duch; F S Pedersen
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

2.  Lack of shielding of primer binding site silencer-mediated repression of an internal promoter in a retrovirus vector by the putative insulators scs, BEAD-1, and HS4.

Authors:  C Modin; F S Pedersen; M Duch
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro.

Authors:  I Hamaguchi; N B Woods; I Panagopoulos; E Andersson; H Mikkola; C Fahlman; R Zufferey; L Carlsson; D Trono; S Karlsson
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes.

Authors:  J M Wilson; N R Chowdhury; M Grossman; R Wajsman; A Epstein; R C Mulligan; J R Chowdhury
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  Negative regulation of the major histocompatibility complex class I promoter in embryonal carcinoma cells.

Authors:  J R Flanagan; M Murata; P A Burke; Y Shirayoshi; E Appella; P A Sharp; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

6.  Promoter interactions in retrovirus vectors introduced into fibroblasts and embryonic stem cells.

Authors:  P Soriano; G Friedrich; P Lawinger
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

7.  The R-U5-5' leader sequence of neurovirulent wild mouse retrovirus contains an element controlling the incubation period of neurodegenerative disease.

Authors:  J L Portis; S Perryman; F J McAtee
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  Poorly expressed endogenous ecotropic provirus of DBA/2 mice encodes a mutant Pr65gag protein that is not myristylated.

Authors:  N G Copeland; N A Jenkins; B Nexø; A M Schultz; A Rein; T Mikkelsen; P Jørgensen
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

9.  Inhibition of Moloney murine leukemia virus-induced leukemia in transgenic mice expressing antisense RNA complementary to the retroviral packaging sequences.

Authors:  L Han; J S Yun; T E Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

10.  Two blocks in Moloney murine leukemia virus expression in undifferentiated F9 embryonal carcinoma cells as determined by transient expression assays.

Authors:  G Feuer; M Taketo; R C Hanecak; H Fan
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.